A Study on How NNC0174-1213 Works in People With Overweight or Obesity.

Exclusion Criteria

• •Known or suspected hypersensitivity to study intervention(s) or related products.
• •Exposure to an investigational medicinal product within 2 months or 5 half-lives of the investigational medicinal product (if known), whichever is longer, before screening.
• •Participants report prior receipt of an amylin and/or calcitonin receptor agonist within the last 6 months.
• •Impaired liver function defined as any of the below:
• •Aspartate aminotransferase (AST) more than or equal to (\>=) 2 times upper limit of normal at screening
• •Alanine aminotransferase (ALT) more than or equal to (\>=) 2 times upper limit of normal at screening
• •Bilirubin more than (\>) 1.5 times upper limit of normal at screening (except if known or proven Gilbert's syndrome)
• •Renal impairment with estimated Glomerular Filtration Rate (eGFR) less than (\<) 75 milliliters per minute per 1.73 square meter (mL/min/1.73 m\^2) at screening.
• •Glycated haemoglobin (HbA1c) more than or equal to (\>=) 6.5 percent (%) (48 millimoles per mole (mmol/mol) at screening.
• •Any clinically significant body weight change more than or equal to (\>=) 5 percent (%) self-reported change) or dieting attempts (e.g., participation in a weight reduction program) within 90 days before screening .
• •Any disorder, unwillingness or inability which in the investigator's opinion, might jeopardize the participant's safety or compliance with the protocol.
• •Any laboratory safety parameters at screening outside the below laboratory ranges, see designated reference range documents for specific values:
• •Vitamin D (25-hydroxycholecalciferol) less than (\<) 12 nanogram per milliliter (ng/mL) (30 nanometer (nM) at screening
• •Parathyroid hormone (PTH) outside normal range at screening
• •Total calcium outside normal range at screening
• •Calcitonin more than or equal to (\>=) 50 nanogram per liter (ng/L) at screening